A Mechanistic Study to Evaluate Impact of Subcutaneous Implants of Afamelanotide on Ultraviolet Radiation-induced DNA Damage and DNA Repair Capacity in Healthy Volunteers With Skin Types I-III
Latest Information Update: 14 Feb 2023
At a glance
- Drugs Afamelanotide (Primary)
- Indications Erythropoietic protoporphyria; Hepatic-porphyria; Pemphigus; Polymorphus light eruptions; Stroke; Vitiligo; Xeroderma pigmentosum
- Focus Therapeutic Use
- Sponsors Clinuvel Pharmaceuticals
- 08 Feb 2023 Status changed from recruiting to completed.
- 02 Feb 2023 According to a Clinuvel Pharmaceuticals media release, company released first results from this trial in nine healthy volunteers, as part of Company's DNA Repair Program.
- 02 Feb 2023 Results presented in a Clinuvel Pharmaceuticals Media Release